Clinical Trials Directory

Trials / Completed

CompletedNCT00414921

Preschool Supplement to Clonidine in ADHD (Kiddie-CAT)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
30 (actual)
Sponsor
University of Cincinnati · Academic / Other
Sex
All
Age
4 Years – 6 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of two medications--clonidine and methylphenidate--alone or in combination to treat attention deficit hyperactivity disorder in children ages 4 through 6.

Detailed description

Attention deficit hyperactivity disorder (ADHD) is a disease characterized by one or more symptoms of hyperactivity, impulsivity, or inattention that interfere with school, home, work, or social settings. ADHD does not have clear physical signs that can be seen in an x-ray or a lab test. The disorder only can be identified by looking for certain behaviors, which vary from person to person. This trial will compare the benefits and side effects of two medications--clonidine and methylphenidate (MPH)--used alone or in combination to treat ADHD in children. MPH is approved by the Food and Drug Administration (FDA) for the treatment of ADHD symptoms in children, and clonidine is FDA-approved for the treatment of hypertension in adults. Stimulant medications such as MPH are known to safely and effectively treat many ADHD symptoms. Such medicines, however, do not cure the condition or improve all ADHD symptoms, and the long-term effectiveness of these medications is not well-known. In this study, participants will be randomly selected to receive one of four treatments: 1) clonidine; 2) MPH; 3) clonidine and MPH; or 4) a placebo (an inactive substance). Participation in the study is about 16 weeks, and includes a baseline screening and 5 evaluation visits to assess attention, hyperactivity, overall improvement and general functioning, medication side effects, blood pressure, pulse, and weight.

Conditions

Interventions

TypeNameDescription
DRUGclonidineClonidine is FDA-approved for the treatment of hypertension in adults
DRUGmethylphenidateMethylphenidate is known to safely and effectively treat many ADHD symptoms.
OTHERplaceboinactive substance

Timeline

Start date
2003-09-01
Completion
2007-06-01
First posted
2006-12-22
Last updated
2009-05-21

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00414921. Inclusion in this directory is not an endorsement.